Skip to content

ANALGESIC EFFICACY OF BUPIVACAINE VERSUS BUPIVACAINE PLUS MAGNESIUM SULPHATE IN TRANSVERSUS ABDOMINIS PLANE BLOCK FOLLOWING ABDOMINAL GYNAECOLOGICAL SURGERY

ANALGESIC EFFICACY OF BUPIVACAINE VERSUS BUPIVACAINE PLUS MAGNESIUM SULPHATE IN TRANSVERSUS ABDOMINIS PLANE BLOCK FOLLOWING ABDOMINAL GYNAECOLOGICAL SURGERY

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
PACTR
Registry ID
PACTR202208499106275
Enrollment
74
Registered
2022-08-10
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign and malignant Gynaecological diseases Anaesthesia

Interventions

Bupivacaine and normal saline
Bupivacaine and Magnesium Sulpate

Sponsors

Olatunde Towobola
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: American Society of Anaesthesiologists physical status class I – III female adults scheduled for elective abdominal surgery

Exclusion criteria

Exclusion criteria: Myomectomy Patients’ refusal History of relevant drug allergies Patients on calcium channel blockers Opioid dependence Localised skin infection at site of block Patient with sepsis Patient with coagulation disorders Obese patients with BMI > 35kg/m2 Psychiatric illness that would interfere with the perception and assessment of pain Intra operative finding of a frozen pelvis Intra operative finding of extensive tissue adhesions

Design outcomes

Primary

MeasureTime frame
To determine the pain scores following TAPB using 0.25% plain bupivacaine with or without MgSO4.

Secondary

MeasureTime frame
Compare duration of analgesia following TAPB using 0.25% plain bupivacaine with or without MgSO4.

Countries

Nigeria

Contacts

Public ContactTolu Alakija

Secretary LASUTH HREC

dcst@lasuth.org+2348055262563

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026